Friday 25 June 2010

Star-studded campaign drives better prostate cancer awareness

June TV Campaign - #03 from Dillon Brice on Vimeo.



Some of Australia’s biggest TV, music, media and sports stars have come together to front a major prostate cancer awareness campaign that offers men clarity about prostate cancer and testing. The campaign has been developed to provide men with clear advice on prostate cancer risk by encouraging men to discuss their individual risk and testing options with their doctor.

Well-respected actors, musicians, sportsmen and media commentators including Bert Newton, Steve Waugh, Gyton Grantley, Kirk Pengilly, Adam Spencer, Simon Westaway, and Marcus Graham, have dedicated their time to appear in a series of television commercials, radio commercials and online videos with the aim of reducing confusion some men feel about prostate cancer and prostate cancer testing. The television commercials were developed by award winning director, Paul Middleditch, of Plaza Films and Josh Whiteman, of The Host Agency. The campaign was shot entirely at The Wiggles Studios, in Sydney and edited by Peter Whitmore, of The Editors.

The driving force for the community awareness campaign was Underbelly and Rescue: Special Ops star Les Hill who personally felt Australian men needed to be further educated about the severity of prostate cancer.

“I was absolutely taken back when I realised that every three hours a man dies as a direct result of prostate cancer. We are talking about thousands of men losing their lives each year when prostate cancer can be treated and cured if detected early,” said Mr Hill.

“The support we have received from people in the sport and entertainment industries has been astounding, and if we are able to at least let men know that all it takes is a chat to your doctor, then we would have already made a difference in our community.”

The campaign has been launched as new research shows the majority of men recognise prostate cancer as the most important men’s health issue (83%), but are seeking further information about the benefits of testing for prostate cancer risks and treatment options.

A survey1 conducted by PCFA found that almost half (40%) of the men surveyed believed the advice given on the benefits of testing for prostate cancer was far too confusing. The survey also found that 41% felt conflicted about treatment options for the disease following a diagnosis.

PCFA’s Chief Executive Officer, Mr Andrew Giles, says we should be committed to educating not only men but the general public on the risks of prostate cancer.

Early detection is the key to enabling better outcomes and potential cure of prostate cancer. Accordingly, PCFA recommends that men at 50 with no family history of prostate cancer, and men at 40 with a family history, should discuss prostate cancer and assess their personal risk each year with their doctor. If deemed necessary, a combination of both a Prostate Specific Antigen (PSA) blood test and a Digital Rectal Examination (DRE) is recommended.

“Testing for prostate cancer should be viewed and discussed at an individual level, PCFA recommends that men talk to their doctors about their individual risk of prostate cancer. As the national peak body, we will continue to support this message in the hope to alleviate the uncertainty around testing and treatment,” said Mr Giles.

Star-studded campaign drives better prostate cancer awareness

Monday 14 June 2010

OEM Partnership with Thought Technology Ltd

Mediwatch plc

OEM Partnership with Thought Technology Ltd.



Mediwatch plc ("Mediwatch" or "the Company", AIM: MDW), the innovative urological diagnostic manufacturing company, and Thought Technology Ltd., the worldwide leading expert in biofeedback, have entered into an OEM agreement to integrate their technology onto the Mediwatch pelvic floor diagnostic platform.

The agreement provides for collaboration between the two groups to offer a range of pelvic floor rehabilitation systems under the Mediwatch "Venus" brand. The new range of products will be sold worldwide by Mediwatch through its direct channels in the USA, UK and its distributors throughout the rest of the world.

Pelvic floor rehabilitation equipment is yet another component of Mediwatch's strategy to develop a "One Stop Shop" approach to the provision of urologic care equipment.

Philip Stimpson, Mediwatch Chief Executive commented:

"This OEM agreement provides Mediwatch with an immediate entry into this expanding marketplace. We continue to look at ways to develop, extend and enhance our One Stop Shop offering for diagnostics all with the aim of providing excellent patient diagnosis and care solutions."

Enquiries

Mediwatch +44 (0)1788 547888 +44 (0)1788 547888
Philip Stimpson, Chief Executive

Fairfax I.S. PLC +44 (0)20 7598 5368 +44 (0)20 7598 5368
Nominated Adviser / Broker

Ewan Leggat / Laura Littley


Editor's Notes

Mediwatch plc: Innovative Diagnostic Solutions

Mediwatch is a leader in its field. The Company is continually striving to develop and market faster, simpler and less invasive diagnostic products to save lives and restore quality of life for people with a variety of urological conditions. Founded in 1995, Mediwatch (www.mediwatch.com) has developed a range of point-of-care medical equipment for the diagnosis of urological disorders.

The business focuses its design skills towards diagnostic products that can be used across the medical profession.

Mediwatch has established excellent foundations for continued growth building on the acquisition and integration of a division of Medtronic Inc in 2007, an international distribution network and its research and development programmes.

Mediwatch has a global presence with offices in both the UK and US. The UK office is the base for manufacturing, research and development, sales and marketing to the rest of the world outside of the US and Canada with a direct sales force for the UK markets. The US office manages a direct sales and marketing infrastructure to cover the US and Canada along with some research and development activities.


Thought Technology Ltd.

Thought Technology, based in Montreal, Canada and founded in 1975, is the world's leading biofeedback and psychophysiological instrument manufacturer. Its instrumentation not only monitors and records a wide variety of physiological and mechanical signals, but also analyzes and feeds back information in real time, through a variety of auditory and visual means.

Thought Technology equipment is used as an essential part of many therapeutic treatments and clinical assessment protocols to treat stress related disorders as well as provide treatment for incontinence and muscle rehabilitation, including EMG-triggered stimulation. On the non-medical side, it is also used in ergonomics, sports and educational applications - wherever accurate and sensitive psychophysiological monitoring and biofeedback are needed.

Thought Technology Ltd. Sports involvement has spanned 35 years, with intensive involvement in the Vancouver 2010 Olympics, and Canada's success of 26 Medals, and a record 14 Gold. The use of ProComp/Infiniti in the MindRoom at AC Milan and other elite Football (soccer) clubs have made the company's Sport involvement legendary.

Enquiries:

Thought Technology Ltd. 1 - 514- 489-8251

Thought Technology Ltd Website

Dr. Hal K. Myers - President
Lawrence Klein - Vice President

Shawn Tian - Sales and Marketing Manager

OEM Partnership with Thought Technology Ltd

Wednesday 9 June 2010

Mediwatch PLC (US) Jobs

Just copying these jobs for reference purposes:

18th May 2010

Direct Sales Representative - Urology

About the Job

Mediwatch USA Inc. is seeking a Direct Sales Representative for Florida to be based out of the South Florida Area. The ideal candidate will have a call pattern and relationships in the Urology/Urogynecology market. Urodynamic/Urology knowledge and experience selling to hospitals, private practices and clinics is required.

Qualifications:
- Bachelors Degree
- 5+ years sales experience to physicians
- professional appearance and demeanor
- Urodynamic experience preferred

Responsibilities:
- sales of urodynamic equipment, supplies, diagnostic tests, ultrasound, biofeedback and medical equipment
- territory management
- product demonstrations (training will be provided)
- cold calling on territory
- candidate will pursue all leads and generate new business
- maintain current customers and requests for product information
- work closely with home office to resolve customer concerns/needs
- maintain records on territory and customer sales
- attend area conferences
- training for new product launches
- contributions to national sales effort by providing knowledge and data

Requirements:
- High Motivation for Sales
- Cold Calling
- Closing Skills
- Demonstrations

Mediwatch is a specialist medical diagnostic company providing a "One-Stop" solution to Urologists and medical practitioners worldwide. Please visit our website for additional company information www.mediwatch.com.

*************************************************************************************
18th May 2010

Diagnostic Equipment Sales Representative - Urology

About the Job

Mediwatch USA Inc. is seeking a Direct Sales Representative to be based out of the San Francisco Area. The ideal candidate will have a call pattern and relationships in the Urology/Urogynecology market. Urodynamic/Urology knowledge and experience selling to hospitals, private practices and clinics is required. Please feel free to visit us at Booth #2414 at the AUA Meeting being held in San Francisco May 29th - June 2nd.


Qualifications:
- Bachelors Degree
- 5+ years sales experience to physicians
- professional appearance and demeanor
- Urodynamic experience preferred

Responsibilities:
- sales of urodynamic equipment, supplies, diagnostic tests, ultrasound, biofeedback and medical equipment
- territory management
- product demonstrations (training will be provided)
- cold calling on territory
- candidate will pursue all leads and generate new business
- maintain current customers and requests for product information
- work closely with home office to resolve customer concerns/needs
- maintain records on territory and customer sales
- attend area conferences
- training for new product launches
- contributions to national sales effort by providing knowledge and data

Requirements:
- High Motivation for Sales
- Cold Calling
- Closing Skills
- Demonstrations

Mediwatch is a specialist medical diagnostic company providing a "One-Stop" solution to Urologists and medical practitioners worldwide. Please visit our website for additional company information www.mediwatch.com.


Visit us at Booth #2414 at the AUA Meeting being held in San Francisco May 29th - June 2nd.

************************************************************************************
18th May 2010

Direct Sales Representative - Urology

About the Job

Mediwatch USA Inc. is seeking a Direct Sales Representative to be based out of the Atlanta Area to cover the state of Georgia. The ideal candidate will have a call pattern and relationships in the Urology/Urogynecology market. Urodynamic/Urology knowledge and experience selling to hospitals, private practices and clinics is required.

Qualifications:
- Bachelors Degree
- 5+ years sales experience to physicians
- professional appearance and demeanor
- Urodynamic experience preferred

Responsibilities:
- sales of urodynamic equipment, supplies, diagnostic tests, ultrasound, biofeedback and medical equipment
- territory management
- product demonstrations (training will be provided)
- cold calling on territory
- candidate will pursue all leads and generate new business
- maintain current customers and requests for product information
- work closely with home office to resolve customer concerns/needs
- maintain records on territory and customer sales
- attend area conferences
- training for new product launches
- contributions to national sales effort by providing knowledge and data

Requirements:
- High Motivation for Sales
- Cold Calling
- Closing Skills
- Demonstrations

Mediwatch is a specialist medical diagnostic company providing a "One-Stop" solution to Urologists and medical practitioners worldwide. Please visit our website for additional company information www.mediwatch.com.

*************************************************************************************
24th May 2010

Software Programmer / Manager

About the Job

Position Overview
The primary job function for this position is to help with and guide the full Software development lifecycle of its software projects. We are looking for someone with proven development experience with C# and WPF that can write code and guide staff working on the project(s)..

You will also be required to get involved in various other functions within the organization.

Essential Job Functions
· Design, Code, Test and deploy .Net based applications.
· Debug current and legacy applications.
· Thorough documentation of system Design, production functions and Support solutions.
· Support and trouble shoot Windows Application and Networking.
· Repair computer hardware at the component level.

Requirements
· Bachelors in Computer Science or related field.
· 5+ Years .Net development experience (.Net 3.5, C#, asp.net, java).
· 5+ Years SQL.
· 3+ Years supporting windows based systems.
· Strong Problem solving skills.

Other Skills/Abilities
· Silverlight or WPF a BIG plus.
· C++ experience is a plus.
· VBA Experience.
· Ability to work alone and in a team.
· Ability to take ownership of tasks.


This is the link but information will no doubt disappear in time:

Mediwatch emplyment USA

A personal message from TV and radio star Neil Fox

9 June 2010

Dear Sir,

It is at this time of the year when men, particularly our Dads, are at the centre of our thoughts and I would like to call on your readers to help raise awareness of the most common cancer in men by supporting The Prostate Cancer Charity’s Father’s Day campaign.

In honour of Father’s Day, Barclays, Clinton Cards and Marks & Spencer are all selling especially selected items to help raise vital funds for a disease which kills one man every hour in the UK – which sadly included my own dad, Roy.

Dad died of prostate cancer when he was 76. When he was diagnosed neither of us had really heard of the prostate let alone what could go wrong with it, or the possible signs and symptoms we should watch out for – perhaps if we had known more, Dad’s story, and therefore our whole family’s, would have been different.

Dad died nine years ago and I still miss him terribly but I’m trying to do something positive to help stop other families having their lives devastated by this disease.

So, come on mums, boys and girls - why not make the 'old man' happy this Father's Day and pop in to your local Barclays, where for a small donation your can get four specially-designed Purple Ronnie badges. Alternatively visit Clinton Cards or Marks & Spencer and pick up some novelty presents, pens or a specially designed card and do your bit to help support the 250,000 men living with prostate cancer in the UK.

Purple Ronnie, the much loved cartoon poet, has already got in on the act and I will leave the final words to him:



Thank you for your help and support,

Neil Fox
Ambassador for The Prostate Cancer Charity

ENDS

A personal message from TV and radio star Neil Fox

From Passion to Action: Us TOO celebrates 20th birthday in August

From 'The "New" Prostate Cancer InfoLink'

Us TOO International — one of the two oldest prostate cancer advocacy and support organizations in the world — will be celebrating its 20th birthday with a major event in Chicago on August 20 and 21 this year, and everyone is invited!
A complete run down on the event is available on the Us TOO web site, and we suggest you click here to get all the details. Us TOO has been able to negotiate special low room rates at the symposium hotel and registration is also very reasonable.

A key feature of the celebration will be the special “Advocacy Summit” to be held in the morning on Friday, August 20th. Over the past two years, a number of prostate cancer not-for-profits have been working together to build “America’s Prostate Cancer Organizations,” a collaborative initiative that has set out to develop and act on consensus initiatives in the area of prostate cancer advocacy. Us TOO is very hopeful that — along with others — representatives of most of all of America’s Prostate Cancer Organizations will be participating in this “Advocacy Summit.” Prostate Cancer International and several others have already made the commitment to attend and has been working with Us TOO International to coordinate this event.

A place where the prostate cancer community still fails to match up with our breast cancer sisters is in motivating our members and the prostate cancer survivor community to take real political action in driving for greater research funding for prostate cancer and ensuring that legislation optimizes the appropriate and early detection of prostate cancer — with specific emphasis on identifying those patients at greatest risk for aggressive forms of prostate cancer that can lead to untimely death or severe loss of quality of life because of advanced or metastatic disease.

Earlier this year, America’s Prostate Cancer Organizations were influential in the development of two Congressional hearings on topics related to prostate cancer, and there have been other small victories as well. But it is time for us all to recognize and accept that bigger victories need a greater involvement from the entire prostate cancer community. We don’t need hours and days of people’s time. But we do need action. We need phone calls to your Congressman or Congresswoman about specific issues. We need e-mails and letters maybe half a dozen times a year to the same people. And we need to really sound as though we care because tens of thousands of voices are brought to bear on the same issues.

Hopefully the “Advocacy Summit” in Chicago can mark a new beginning. So see if you can find a little time in August for a trip to The Windy City. In the supposedly immortal words attributed to Benjamin Franklin at the signing of the Declaration of Independence, “We must, indeed, all hang together, or assuredly we shall all hang separately.”

From Passion to Action: Us TOO celebrates 20th birthday in August

Tuesday 8 June 2010

NEWS-Week Ending 13th June(Updated-3 Posts)

Regular Check-Ups Key To Beating Prostate Cancer USA-11th June

Welsh research gives new hope to men with prostate cancer UK-9th June

Genetic Markers Could Predict Prostate Cancer In Younger Men USA-8th June

Distribution Agreement with GE Healthcare

Mediwatch plc enters into a distribution agreement with GE Healthcare


Mediwatch plc ("Mediwatch" or "the Company") (AIM: MDW), the innovative urological diagnostic manufacturing company, has entered into an agreement with GE Healthcare to distribute its ultrasound devices to selected areas in the US.

Under the terms of the agreement, Mediwatch will distribute GE Healthcare's ultrasound products for urology, nephrology, uro-gynecology and radiation oncology (urologic applications) practices.

"Mediwatch is proud to have the opportunity to market GE Healthcare's leading ultrasound technology in the US with our innovative range of products," said Philip Stimpson, Chief Executive Officer of Mediwatch. "The addition of GE Healthcare's ultrasound products will enhance our ability to offer a single source solution for urology healthcare providers."

Mediwatch plc enters into a distribution agreement with GE Healthcare



About Mediwatch plc:

Mediwatch is a leader in its field. The Company is continually striving to develop and market faster, simpler and less invasive diagnostic products to help save lives and restore quality of life for people with a variety of urological conditions. Founded in 1995, Mediwatch (www.mediwatch.com) has developed a range of point-of-care medical equipment for the diagnosis of urological disorders.

The business focuses its design skills towards diagnostic products that can be used across the medical profession.

Mediwatch has established excellent foundations for continued growth building on the acquisition and integration of a division of Medtronic Inc in 2007, an international distribution network and its research and development programmes.

Mediwatch has a global presence with offices in both the UK and US. The UK office is the base for manufacturing, research and development, sales and marketing to the rest of the world outside of the US and Canada with a direct sales force for the UK markets. The US office manages a direct sales and marketing infrastructure to cover the US and Canada along with some research and development activities.



About GE Healthcare:

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $16 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.



For our latest news, please visit http://newsroom.gehealthcare.com

Distribution Agreement with GE Healthcare

Monday 7 June 2010

June-Music,Film and the odd England joke spot(Updated 1st July)

But only another 4 years to WAIT! :-)










AFTER THE FIRST TWO GAMES,CLUTCHING AT STRAWS NOW!








Sunday 6 June 2010

Mediwatch Distributors-Iran

Will follow this post up another time:

Welcome to TGS website


Tajhiz Gostaresh Sina is a leading medical company which is in partnership with more than 10 well known medical companies all over the world. This company has been established in 2003, in Tehran, Iran. Our activities are now very well advanced all across the Country. We provide medical issues for almost every hospital which is involved with fields of medicine such as: Neurology, Gastroenterology, Medical Imaging, Rehabilitation, Urology, Diagnostic and General Surgery, Sterilization and Operating Rooms.
We are glad if you take your time by browsing in our website.

Tajhiz Gostaresh Sina

Urology Products

Device Technologies-Australian Division Award

Device Takes Home Robot Gong

26th May 2010



Intuitive Surgical recently held their World Wide Distributors meeting in Sunnyvale California. Device Technologies was please to yet again take home the award for the Leading Distributor for our region. The award is based on installations of systems as well utilisation. Outside of Korea (who have some funding anomalies), Device Technologies runs the busiest da Vinci programs in the world.

Kevin Ryan and Peter Ord were on hand with Mick Shaddock and Heath Priestly to accept the honour at the awards dinner. Device Technologies is seen a global leader in the development of the da Vinci Surgery market. So much so that Peter Ord was asked to address the meeting and discuss the strategies that have lead to the continued success.

The meeting, comprised of 140 delegates from around the Globe, were all ears as Peter gave a 30 minute presentation. He highlighted the level of Customer service provided by Technical Service team as well as Marketing & Sales teams as integral to the on going success.

Device Takes Home Robot Gong

Other posts relating to Device Technologies:

(Australia) Device Technologies-Website Update

DISTRIBUTORS FOR MEDIWATCH PRODUCTS

Friday 4 June 2010

NEWS-Week Ending 6th June(Updated-7 posts)

York to host top cancer conference UK-4th June

Mark Bright swaps his football for a bicycle in support of The Prostate Cancer Charity UK-4th June

Prostate cancer danger warning for Glasgow men UK-3rd June

Men 'underestimate prostate cancer risk' UK-3rd June

The Prostate Cancer Charity comments on new nanoparticle PSA test to detect prostate cancer recurrence UK-3rd June

New form of PSA test is 1,700 times more sensitive USA-3rd June

The Prostate Cancer Charity enters the scrum as it joins forces with the RugbyRocks festival UK-2nd June

258,000 prostate cancer deaths worldwide in 2008

Another article from 'The "New" Prostate Cancer InfoLink':

The recently announced GLOBOCAN 2008 assessment of the worldwide burden of cancer includes a global estimate of 258,000 deaths from prostate cancer in 2008, and a global incidence of 913,000 cases of prostate cancer that same year.
GLOBOCAN 2008 is a project of the International Agency for Research on Cancer. Cancer data is available by country and region as well as by type 0f cancer. However, you can just click on the following link to view the basic global prostate cancer data.

Based on these data, worldwide, prostate cancer is the second most common form of cancer diagnosed in men, the fifth most common cancer overall, and the sixth leading cause of death from cancer in men. The fact that prostate cancer is “only” the sixth leading cause of death from cancer overall may come as a surprise to some readers, since it is the second leading cause of cancer death among males in the USA. However, in many parts of the world, there are multiple reasons why men may die of other causes — including other forms of cancer — long before they can have prostate cancer diagnosed or they are likely to die from this form of cancer.

The GLOBOCAN 2008 database confirms that prostate cancer mortality rates are generally higher in populations which are of predominantly black African origin (such as the Caribbean and sub-Saharan Africa), very low in Asia, and of intermediate values in Europe countries and Oceania. It is interesting to note that while the incidence of prostate cancer is 3.2 times higher in the USA than it is in Russia (as just one example), the mortality rates from prostate cancer in these two nations are very similar (at 9.7/100,000 in the USA and 10.8/100,000 in Russia). This reflects the fact that PSA testing is significantly more common in the USA, but does not appear necessarily seem to translate into a major impact on mortality rates — even though men in the USA tend to have a notably higher life expectancy than men in Russia.

258,000 prostate cancer deaths worldwide in 2008

Tuesday 1 June 2010

More from the AUA in San Francisco

I'm always interested in what 'The "New" Prostate Cancer InfoLink' have to say so I hope they don't object to me copying yet another one of their articles here:

"Posted on June 1, 2010 by Sitemaster

The most interesting thing about the educational process at the AUA this year is the increasing appreciation of the complexity of the decision-making processes required by patients and their doctors as regards prostate cancer risk and management.
After sitting through multiple sessions and discussions at which few really “new” data have been presented, your correspondent is struck by the fact that, for all the increase in data and information that is meant to be able to help a doctor and his patient make good decisions about treatment, what has actually happened over the past decade is that we may have just made the decisions more difficult for most patients and their doctors — with little actual long-term benefit.

Many in the urology community seem, themselves, to be at a loss as to how best to help their patients — particularly those diagnosed with low risk disease. Although we have an expanding range of therapeutic options for the treatment of early stage prostate cancer, knowing which form of management is going to be most appropriate and effective for an individual patient is an almost impossible task. And for those who decide that active surveillance is a reasonable means of managing their condition, there are significant differences of opinion about how to make the best possible decision to come off active surveillance and move to treatment when this is really necessary.

In a state-of-the-art lecture, later today, Dr. Eric Klein of the Cleveland Clinic will present the hypothesis that “Prostate cancer may be an infectious disease.” We have to say that this is probably not the best title for this lecture — catchy though it is. What Dr. Klein will actually do is review available data suggesting that the XMRV retrovirus may act as a trigger for development of certain types of prostate cancer in men who harbor this virus. As yet there is no clear evidence that the XMRV virus either triggers the development of prostate cancer or causes this form of cancer. And while it does appear possible that XMRV infection may lead to the development of prostate cancer in some men, it seems highly unlikely to your correspondent that the presence of XMRV is the only reason for development of prostate cancer. In other words, prostate cancer is still going to be found in men who have never been infected by XMRV.

From a patient point of view, we are at a point in time where there is enormous development in our technical skills to diagnose and treat patients with prostate cancer, but what we also need is some real movement in the area of application of all of this development in the best interests of the patient. Knowing what we can do is not even close to helping an individual patient and his doctors to know what they should do in the best interests of that patient."

More from the AUA in San Francisco

FUTURE EVENTS AND LATEST NEWS(Updated-22nd June)

Latest News

OEM Partnership with Thought Technology Ltd Mediwatch-14th June

Distribution Agreement with GE Healthcare Mediwatch-8th June


Mediwatch Training Courses

Mediwatch USA- Basic Urodynamics Clinicians’ Workshop 26,27 June 2010


Future Events

Advances in Urogynecology &
Reconstructive Pelvic Surgery
USA-10th to 12th June




32nd British International Congress of Obstetrics and Gynaecology (BICOG 2010) UK(Belfast)-20th to 23rd June




BAUS Annual Meeting UK(Manchester)-21st to 24th June




STUFF THAT MAYBE DID BUT NOW
DOESN'T FIT IN WITH THE TITLE...


Director Shareholding 4th May

Director Shareholding 14th April


Mediwatch Annual Report 2009


December/January Mediwatch Newsletter

Mediwatch Interim Results for the six month ended 30 April 2009

Five year global distribution agreement secured with Inverness Medical Innovations-16 March 2009

Preliminary Results for the year ended 31 October 2008-Issued 26 January 2009